How can we reduce late stage failures? - Creating an accelerated PoC operation


  • Global pharma company faced with shrinking R&D budget
  • Poor track record in progressing in-house innovation through to market:
    • High failure rate
    • Excessively costly


  • Major program working with leadership teams of Research and Development to examine the issues resulting at the R to D interface
  • Re-designed R to D interface to enable expedited Proof of Concept
  • New processes, new objectives, new governance responsibilities and mechanisms
  • Design and implementation planning


  • New interface enabled ‘Fast fail’ – earlier, better informed decision making and saving significant costs associated with late stage failures
  • Research accountability extended to PoC
  • Improved flow of quality candidates from Research
  • Improved knowledge sharing between Development, Preclinical and Research
Related capabilities